ChemoCentryx, Inc. (NASDAQ: CCXI) Securities Fraud Class Action:
The lawsuit focuses on ChemoCentryx s statements about its new drug application ( NDA ) for its vasculitis drug candidate Avacopan.
Beginning on Nov. 25, 2019, ChemoCentryx touted positive topline data from its Pivotal Phase III ADVOCATE trial demonstrating Avacopan s superiority over standard of care in ANCA-associated vasculitis and that the trial met both of its primary endpoints. This and subsequent positive announcements sent the price of CCXI soaring.
The complaint alleges ChemoCentryx concealed that: (1) the trial s study design was flawed; (2) data from the trial raised serious safety concerns; and (3) these issues presented a substantial concern about the viability of ChemoCentryx s NDA.
Home / Top News / HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages SOS Investors to Contact its Attorneys Now, Securities Class Action Filed and Application Deadline Approaching
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages SOS Investors to Contact its Attorneys Now, Securities Class Action Filed and Application Deadline Approaching
SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) Hagens Berman urges SOS Limited
(NYSE: SOS) investors to submit their losses now.
Class Period: July 22, 2020 – Feb. 25, 2021
Lead Plaintiff Deadline: June 1, 2021
Visit: www.hbsslaw.com/investor-fraud/SOS
SOS Limited (SOS) Securities Fraud Class Action:
The complaint centers on SOS’s purported entry into the bitcoin mining business. On Jan. 21, 2021, SOS claimed it purchased over 15,000 mining rigs from HY International Group New York (“HY”), and a month later, claimed that 5,000 mining rigs had gone live.
Home / Top News / HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Emergent BioSolutions (EBS) Investors with $100k+ Losses to Contact its Attorneys Now, Securities Class Action Filed, Application Deadline Approaching
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Emergent BioSolutions (EBS) Investors with $100k+ Losses to Contact its Attorneys Now, Securities Class Action Filed, Application Deadline Approaching
SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) Hagens Berman urges Emergent BioSolutions Inc.
(NYSE: EBS) investors with $100k or more losses to submit your losses now.
Class Period: July 6, 2020 – Mar. 31, 2021
Lead Plaintiff Deadline: June 18, 2021
Visit: www.hbsslaw.com/investor-fraud/ebs
844-916-0895
Emergent BioSolutions (NYSE: EBS) Securities Fraud Class Action:
Home / Top News / HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Amdocs Limited (DOX) Investors of Securities Class Action and Approaching Deadline, Encourages Investors with Losses to Contact Its Attorneys Now
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Amdocs Limited (DOX) Investors of Securities Class Action and Approaching Deadline, Encourages Investors with Losses to Contact Its Attorneys Now
SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) Hagens Berman urges Amdocs Limited
(NASDAQ: DOX) investors with significant losses to submit your losses now.
Class Period: Dec. 13, 2016 – Mar. 30, 2021
Lead Plaintiff Deadline: June 8, 2021
Visit: www.hbsslaw.com/cases/DOX
Amdocs Limited (NASDAQ: DOX) Securities Fraud Class Action:
The complaint alleges that Defendants misrepresented and omitted material facts, including that: (i) Amdocs overstated its profits, cash, and liquidity, while understating its
Home / Top News / HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts XL Fleet (XL) Investors to Imminent May 7th Deadline in Securities Class Action, Advises Investors with Significant Losses to Contact the Firm Immediately
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts XL Fleet (XL) Investors to Imminent May 7th Deadline in Securities Class Action, Advises Investors with Significant Losses to Contact the Firm Immediately
SAN FRANCISCO, May 01, 2021 (GLOBE NEWSWIRE) Hagens Berman urges XL Fleet Corp.
(NYSE: XL) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims.
Class Period: Oct. 2, 2020 – Mar. 2, 2021